As of Monday, October 12, Pacific Biosciences of California, Inc.’s PACB share price has dipped by 10.09%, which has ...

In the latest trading session, Pacific Biosciences of California (PACB) closed at $1.62, marking a +2.53% move from the previous day. The stock exceeded the S&P 500, which registered a gain of 0.51% ...

In the latest trading session, Pacific Biosciences of California (PACB) closed at $1.99, marking a -2.93% move from the ...

Pacific Biosciences (NASDAQ:PACB) has been analyzed by 6 analysts in the last three months, revealing a diverse range of perspectives from bullish to bearish. The following table encapsulates their ...

Pacific Biosciences (ISIN US69404D1081) has a consensus 12-month price target of USD 1.71 from six brokerages, while the ...

The average one-year price target for Pacific Biosciences of California (BMV:PACB) has been revised to MX$38.33 / share. This is a decrease of 28.85% from the prior estimate of MX$53.87 dated May 13, ...

Pacific Biosciences of California (PACB) appears an attractive pick, as it has been recently upgraded to a Zacks Rank #2 (Buy). This upgrade is essentially a reflection of an upward trend in earnings ...

MENLO PARK, Calif. (AP) — MENLO PARK, Calif. (AP) — Pacific Biosciences of California Inc. (PACB) on Wednesday reported a loss of $44.7 million in its second quarter. On a per-share basis, the Menlo ...

Zacks reported that Pacific Biosciences reduced its full-year 2026 revenue guidance to USD 155.00 million to USD 165.00 ...

On Friday, March 21, 2025, the Cathie Wood-led Ark Invest made some notable trades, including significant buys and sells. Ark Invest's fund bought Iridium Communications Inc. (NASDAQ:IRDM), Beam ...

Pacific Biosciences of California (PACB) surged intraday on Friday after its 2Q 2013 earnings release. By midday, the company's stock had jumped over 8%. Pacific Biosciences is a developing ...